DDInter1763 DDInter1077
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Temsirolimus {u} (Compound) downregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lisinopril
Lisinopril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Temsirolimus {u} (Compound) upregulates {v} (Gene) CDK19
CDK19 {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Temsirolimus {u} (Compound) downregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is downregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Temsirolimus {u} (Compound) upregulates {v} (Gene) CDK19
CDK19 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Temsirolimus {u} (Compound) downregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atorvastatin
Atorvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Temsirolimus {u} (Compound) upregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liraglutide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liraglutide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Temsirolimus (Compound) downregulates SMARCD2 (Gene) and SMARCD2 (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Temsirolimus (Compound) upregulates CDK19 (Gene) and CDK19 (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Temsirolimus (Compound) downregulates SMARCD2 (Gene) and SMARCD2 (Gene) is downregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Temsirolimus (Compound) upregulates CDK19 (Gene) and CDK19 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Temsirolimus (Compound) downregulates SMARCD2 (Gene) and SMARCD2 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Temsirolimus (Compound) upregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide